BioSpace News Archive

AbbVie (NYSE: ABBV) will announce its second-quarter 2020 financial results on Friday, July 31, 2020 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time . It will be accessible through AbbVie’s Investor Relations website investors.abbvie.com . An archived edition of

Medical technology and data company Neural Analytics, Inc. announced a name change and rebranding as NovaSignal Corp., representing its expansion into new markets and accelerated commercialization of its life-saving solutions that measure blood flow in the brain. NovaSignal aims to make measuring blood flow to the brain widespread, personal, and portable. Its goal is to make this measurement the “fifth vital sign” along with body temperature, bl

- Imprime PGG, a novel immune activator, has undergone rigorous Phase II testing for the treatment of metastatic breast cancer - Biothera president and chief scientific officer, Jeremy R. Graff, Ph.D., will assume the role of chief development officer at HiberCell

Tessera Therapeutics emerges from three years of stealth operations to pioneer Gene Writing™ as a new genome engineering technology and category of genetic medicine

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first patient has been dosed in its Phase 1 trial evaluating CA-4948,

Pear Therapeutics, Inc. (“Pear” or the “Company”) today announced that it closed a credit facility for up to $50 million from Perceptive Advisors (“Perceptive”), a leading life sciences investment firm. In connection with the financing, Pear issued warrants to Perceptive, and Sam Chawla of Perceptive received board observer rig

Top-Line Results from First of Two Planned Clinical Trials Based on Tear RASP Levels Expected by the End of 2020 New Drug Application Submission for Reproxalap in Dry Eye Disease Expected by the End of 2021 Based on Current Operating Plans, Current Cash Expected to Support Operations into 2022, Consistent with Prior Guidance LEXINGTON, Mass.--( BUSINESS WIRE )-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-st

MAIA Biotechnology, Inc. , a targeted therapy, immuno-oncology company focused on development of first-in-class drugs, announced today that encouraging preclinical results supporting newly-identified immunogenic effects of the company’s lead product candidate, investigational THIO (6-thio-dG), the

New location provides pharmacy services and home delivery to its growing base of hospice patients in the Greater Philadelphia area and Northeastern US.

jCyte Inc. , a biotech company dedicated to preserving and restoring vision in patients with retinitis pigmentosa and other degenerative retinal disorders, announced today that results from the Phase 2b clinical trial of jCell in retinitis pigmentosa will be presented at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting, held July 24-26, 2020. jCell is a first-in-class investigation